These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
431 related articles for article (PubMed ID: 32034076)
21. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Loehr A; Hussain A; Patnaik A; Bryce AH; Castellano D; Font A; Shapiro J; Zhang J; Sautois B; Vogelzang NJ; Chatta G; Courtney K; Harzstark A; Ricci F; Despain D; Watkins S; King C; Nguyen M; Simmons AD; Chowdhury S; Abida W Eur Urol; 2023 Mar; 83(3):200-209. PubMed ID: 36243543 [TBL] [Abstract][Full Text] [Related]
22. Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression. Lheureux S; Prokopec SD; Oldfield LE; Gonzalez-Ochoa E; Bruce JP; Wong D; Danesh A; Torti D; Torchia J; Fortuna A; Singh S; Irving M; Marsh K; Lam B; Speers V; Yosifova A; Oaknin A; Madariaga A; Dhani NC; Bowering V; Oza AM; Pugh TJ Clin Cancer Res; 2023 Sep; 29(18):3706-3716. PubMed ID: 37327320 [TBL] [Abstract][Full Text] [Related]
23. BRCA1, BRCA2, and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer. Richau CS; Scherer NM; Matta BP; de Armas EM; de Barros Moreira FC; Bergmann A; Pereira Chaves CB; Boroni M; Dos Santos ACE; Moreira MAM Cancer Med; 2024 Feb; 13(3):e6729. PubMed ID: 38308422 [TBL] [Abstract][Full Text] [Related]
24. Setting a diagnostic benchmark for tumor BRCA testing: detection of BRCA1 and BRCA2 large genomic rearrangements in FFPE tissue - A pilot study. Valtcheva N; Nguyen-Sträuli BD; Wagner U; Freiberger SN; Varga Z; Britschgi C; Dedes KJ; Rechsteiner MP Exp Mol Pathol; 2021 Dec; 123():104705. PubMed ID: 34637782 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of the Ion Torrent PGM sequencing workflow for the routine rapid detection of BRCA1 and BRCA2 germline mutations. Zanella I; Merola F; Biasiotto G; Archetti S; Spinelli E; Di Lorenzo D Exp Mol Pathol; 2017 Apr; 102(2):314-320. PubMed ID: 28263838 [TBL] [Abstract][Full Text] [Related]
26. Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. Walsh EM; Mangini N; Fetting J; Armstrong D; Chan IS; Connolly RM; Fiallos K; Lehman J; Nunes R; Petry D; Reynolds J; Shah M; Smith KL; Visvanathan K; Lauring J; Park BH; Stearns V; Wolff AC Clin Breast Cancer; 2022 Jun; 22(4):319-325. PubMed ID: 35074264 [TBL] [Abstract][Full Text] [Related]
27. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic. Winter C; Nilsson MP; Olsson E; George AM; Chen Y; Kvist A; Törngren T; Vallon-Christersson J; Hegardt C; Häkkinen J; Jönsson G; Grabau D; Malmberg M; Kristoffersson U; Rehn M; Gruvberger-Saal SK; Larsson C; Borg Å; Loman N; Saal LH Ann Oncol; 2016 Aug; 27(8):1532-8. PubMed ID: 27194814 [TBL] [Abstract][Full Text] [Related]
29. Acquired multiple secondary Tao H; Liu S; Huang D; Han X; Wu X; Shao YW; Hu Y Am J Transl Res; 2020; 12(2):612-617. PubMed ID: 32194909 [TBL] [Abstract][Full Text] [Related]
30. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients. Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111 [TBL] [Abstract][Full Text] [Related]
31. BRCA1/2 testing: therapeutic implications for breast cancer management. Tung NM; Garber JE Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226 [TBL] [Abstract][Full Text] [Related]
32. Recurrent BRCA1 Mutation, but no BRCA2 Mutation, in Vietnamese Patients with Ovarian Carcinoma Detected with Next Generation Sequencing. Vu HA; Phu ND; Khuong LT; Hoa PH; Nhu BTH; Nhan VT; Thanh LQ; Sinh ND; Chi HT; Quan ND; Binh NT Asian Pac J Cancer Prev; 2020 Aug; 21(8):2331-2335. PubMed ID: 32856862 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study. Joris S; Denys H; Collignon J; Rasschaert M; T'Kint de Roodenbeke D; Duhoux FP; Canon JL; Tejpar S; Mebis J; Decoster L; Aftimos P; De Grève J ESMO Open; 2023 Dec; 8(6):102041. PubMed ID: 37852034 [TBL] [Abstract][Full Text] [Related]
34. Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes. Momtaz P; O'Connor CA; Chou JF; Capanu M; Park W; Bandlamudi C; Berger MF; Kelsen DP; Suehnholz SP; Chakravarty D; Yu KH; Varghese AM; Zervoudakis A; Li J; Ku GY; Park JS; Shcherba M; Harding JJ; Goldberg Z; Abou-Alfa GK; Salo-Mullen EE; Stadler ZK; Iacobuzio-Donahue CA; O'Reilly EM Cancer; 2021 Dec; 127(23):4393-4402. PubMed ID: 34351646 [TBL] [Abstract][Full Text] [Related]
35. Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients. Rodriguez-Freixinos V; Fariñas-Madrid L; Gil-Martin M; Barretina-Ginesta P; Romeo M; Villacampa G; Pardo B; Ahmed H; Recalde S; Piulats JM; Gómez-Plaza MC; Gil-Moreno A; Sala E; Martínez-Román S; Ponce J; Meléndez C; Carballas E; Dienstmann R; Oaknin A Gynecol Oncol; 2019 Feb; 152(2):270-277. PubMed ID: 30551885 [TBL] [Abstract][Full Text] [Related]
36. Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report. Simmons AD; Nguyen M; Pintus E BMC Cancer; 2020 Mar; 20(1):215. PubMed ID: 32171277 [TBL] [Abstract][Full Text] [Related]
37. BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Stordal B; Timms K; Farrelly A; Gallagher D; Busschots S; Renaud M; Thery J; Williams D; Potter J; Tran T; Korpanty G; Cremona M; Carey M; Li J; Li Y; Aslan O; O'Leary JJ; Mills GB; Hennessy BT Mol Oncol; 2013 Jun; 7(3):567-79. PubMed ID: 23415752 [TBL] [Abstract][Full Text] [Related]
38. Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in Reiss KA; Mick R; O'Hara MH; Teitelbaum U; Karasic TB; Schneider C; Cowden S; Southwell T; Romeo J; Izgur N; Hannan ZM; Tondon R; Nathanson K; Vonderheide RH; Wattenberg MM; Beatty G; Domchek SM J Clin Oncol; 2021 Aug; 39(22):2497-2505. PubMed ID: 33970687 [TBL] [Abstract][Full Text] [Related]
39. Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing. Triner D; Graf RP; Madison RW; Gjoerup O; Tukachinsky H; Ross JS; Quintanilha JCF; Li G; Cheng HH; Pritchard CC; Zurita AJ; Qin Q; Zhang T; Agarwal N; Reichert ZR; Mateo J; Cieslik M; Morgan TM ESMO Open; 2024 Sep; 9(9):103684. PubMed ID: 39255537 [TBL] [Abstract][Full Text] [Related]
40. Somatic mutations in BRCA1&2 in 201 unselected ovarian carcinoma samples - single institution study. Kowalik A; Zalewski K; Kopczyński J; Siołek M; Lech M; Hińcza K; Kalisz J; Chrapek M; Zięba S; Furmańczyk J; Jedliński M; Chłopek M; Misiek M; Góźdź S Pol J Pathol; 2019; 70(2):115-126. PubMed ID: 31556562 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]